small molecule

BRENZAVVY

BEXAGLIFLOZIN

Loss of exclusivityOctober 2041latest FDA-listed patent expiry

CompanyTHERACOSBIO LLC

Drug detail

Brand name	BRENZAVVY
Active ingredient	BEXAGLIFLOZIN
Strength	20MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	January 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
12594243	October 2041	product
8987323	May 2032	substance, product
10533032	July 2031	use U-2214
10981942	June 2031	substance, product
7838499	January 2029	substance, product
8106021	August 2028	use U-2214
8802637	August 2028	substance, product

Regulatory exclusivity

Code	Expires
NCE	January 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.